{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:31:36Z","timestamp":1793633496809,"version":"4.5.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.omtn.2026.103113","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:56:37Z","timestamp":1790265397000},"page":"103113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-PD-L1 scFv-secreting fifth-generation GD2-CAR T cells enhance antitumor function against GD2-low retinoblastoma"],"prefix":"10.1016","volume":"37","author":[{"given":"Pornpimon","family":"Yuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5937-9571","authenticated-orcid":false,"given":"Katesara","family":"Kongkla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunghathai","family":"Sawasdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6402-7195","authenticated-orcid":false,"given":"Yupanun","family":"Wutti-in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaporn","family":"Phanthaphol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naravat","family":"Poungvarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-8031","authenticated-orcid":false,"given":"Jatuporn","family":"Sujjitjoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103113_bib1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/ped.14498","article-title":"Clinical outcomes and prognosis of Thai retinoblastoma patients","volume":"63","author":"Prajantawanich","year":"2021","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.omtn.2026.103113_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.822330","article-title":"Treatment of Retinoblastoma: What Is the Latest and What Is the Future","volume":"12","author":"Schaiquevich","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtn.2026.103113_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007798","article-title":"Neuroblastoma: an ongoing cold front for cancer immunotherapy","volume":"11","author":"Kennedy","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.103113_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103113_bib5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.33192\/smj.v76i5.268031","article-title":"Cancer Immunotherapy: Challenges and Advancements in CAR T Cell Technology","volume":"76","author":"Yenchitsomanus","year":"2024","journal-title":"Siriraj Med. J."},{"key":"10.1016\/j.omtn.2026.103113_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103113_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2159-8290.CD-NB2017-155","article-title":"FDA Approves Second CAR T-cell Therapy","volume":"8","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2026.103113_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103113_bib9","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14712598.2018.1533951","article-title":"Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia","volume":"18","author":"Thomas","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtn.2026.103113_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103113_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.omtn.2026.103113_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.omtn.2026.103113_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/iovs.62.2.6","article-title":"Retinoblastoma Is Characterized by a Cold, CD8+ Cell Poor, PD-L1- Microenvironment, Which Turns Into Hot, CD8+ Cell Rich, PD-L1+ After Chemotherapy","volume":"62","author":"Miracco","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtn.2026.103113_bib14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1186\/s12885-019-6131-1","article-title":"CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing","volume":"19","author":"Andersch","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omtn.2026.103113_bib15","article-title":"Prospects of anti-GD2 immunotherapy for retinoblastoma","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.103113_bib16","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-24-0221","article-title":"Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells","volume":"30","author":"Pascual-Pasto","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.103113_bib17","first-page":"290","article-title":"EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy","volume":"18","author":"Mitra","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.omtn.2026.103113_bib18","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtn.2026.103113_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100971","article-title":"GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction","volume":"14","author":"Sujjitjoon","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omtn.2026.103113_bib20","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/s41598-025-34331-6","article-title":"B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma","volume":"16","author":"Sujjitjoon","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103113_bib21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-015-0399-5","article-title":"Dinutuximab: first global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.103113_bib22","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2147\/OTT.S228532","article-title":"Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway","volume":"13","author":"Wang","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.omtn.2026.103113_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omtn.2026.103113_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109442","article-title":"Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition","volume":"113","author":"Yuti","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omtn.2026.103113_bib25","article-title":"Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains","volume":"11","author":"Wutti-In","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtn.2026.103113_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric Antigen Receptor T Cells Targeting Integrin alphavbeta6 Expressed on Cholangiocarcinoma Cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtn.2026.103113_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119897","article-title":"Triple-costimulatory GD2-CAR T cells incorporating CD28, 4-1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models","volume":"203","author":"Sujjitjoon","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omtn.2026.103113_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omtn.2026.103113_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/s12967-025-06453-y","article-title":"Enhanced cytotoxicity against cholangiocarcinoma by fifth-generation chimeric antigen receptor T cells targeting integrin alphavbeta6 and secreting anti-PD-L1 scFv","volume":"23","author":"Phanthaphol","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103113_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40265-021-01467-4","article-title":"Naxitamab: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.103113_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2026.120115","article-title":"The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy","volume":"1873","author":"Gabriel","year":"2026","journal-title":"Biochim. Biophys. Acta. Mol. Cell Res."},{"key":"10.1016\/j.omtn.2026.103113_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110400","article-title":"IFNgamma-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling","volume":"97","author":"Padmanabhan","year":"2022","journal-title":"Cell. Signal."},{"key":"10.1016\/j.omtn.2026.103113_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18132-0","article-title":"IFNgamma induces PD-L1 overexpression by JAK2\/STAT1\/IRF-1 signaling in EBV-positive gastric carcinoma","volume":"7","author":"Moon","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103113_bib34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103113_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101663","article-title":"GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy","volume":"32","author":"Zhang","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omtn.2026.103113_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/1545-5017.70334","article-title":"Intravitreal GD2-Specific Chimeric Antigen Receptor T-Cell Therapy for Refractory Retinoblastoma","volume":"73","author":"Subhadhirasakul","year":"2026","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omtn.2026.103113_bib37","first-page":"2228","article-title":"Effects of gamma-interferon on human trabecular meshwork cell phagocytosis","volume":"34","author":"Park","year":"1993","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtn.2026.103113_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5005\/jp-journals-10078-1236","article-title":"Pathogenesis of Uveitic Glaucoma","volume":"12","author":"Kalogeropoulos","year":"2018","journal-title":"J. Curr. Glaucoma Pract."},{"key":"10.1016\/j.omtn.2026.103113_bib39","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103113_bib40","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103113_bib41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4161\/onci.19864","article-title":"Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo","volume":"1","author":"Cheung","year":"2012","journal-title":"Oncoimmunology"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:18:33Z","timestamp":1793632713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2162253126002842"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103113","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD-L1 scFv-secreting fifth-generation GD2-CAR T cells enhance antitumor function against GD2-low retinoblastoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103113"}}